FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study-Reference-Cited by-同舟云学术

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study

Published:2020-04 Issue:4 Volume:5 Page:362-373
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Newsome Philip N,Sasso Magali,Deeks Jonathan J,Paredes Angelo,Boursier Jérôme,Chan Wah-Kheong,Yilmaz Yusuf,Czernichow Sébastien,Zheng Ming-Hua,Wong Vincent Wai-Sun,Allison Michael,Tsochatzis Emmanuel,Anstee Quentin M,Sheridan David A,Eddowes Peter J,Guha Indra N,Cobbold Jeremy F,Paradis Valérie,Bedossa Pierre,Miette Véronique,Fournier-Poizat Céline,Sandrin Laurent,Harrison Stephen A

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference27 articles.

1. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention;Younossi;Nat Rev Gastroenterol Hepatol,2017

2. Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European Liver Transplant Registry study;Haldar;J Hepatol,2019

3. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States;Charlton;Gastroenterology,2011

4. Non-alcoholic fatty liver disease and the interface between primary and secondary care;Tsochatzis;Lancet Gastroenterol Hepatol,2018

5. Past, present and future perspectives in nonalcoholic fatty liver disease;Sanyal;Nat Rev Gastroenterol Hepatol,2019

Cited by 487 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Central Obesity is an Independent Determinant of Advanced Fibrosis in Lean Patients With Nonalcoholic Fatty Liver Disease;Journal of Clinical and Experimental Hepatology;2025-01

2. Probiotics may be useful for drug-induced liver dysfunction in patients with depression – A secondary analysis of a randomized clinical trial;Clinical Nutrition ESPEN;2024-10

3. Epidemiological Study on the Interaction between the PNPLA3 (rs738409) and Gut Microbiota in Metabolic Dysfunction-Associated Steatotic Liver Disease;Genes;2024-09-06

4. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD);Journal of Hepatology;2024-09

5. Cardiovascular risk in US adults with nonalcoholic steatohepatitis (NASH) vs. matched non-NASH controls, National Health and Nutrition Examination Survey, 2017–2020;PLOS ONE;2024-08-27